Steven Charlton

Company: OMass Therapeutics

Job title: Vice President, Pharmacology

Seminars:

Optimising Binding Kinetics Yields Insurmountable MC2 Receptor Antagonists for the Treatment of Diseases of ACTH Excess 4:00 pm

Diseases such as Cushing’s and Congenital Adrenal Hyperplasia are characterised by supraphysiological levels of the hormone ACTH. MC2R antagonists should inhibit this effect, but are at risk of being out-competed by high ACTH levels, resulting in very high doses being required for efficacy This talk will describe the discovery and characterisation of MC2R antagonists with…Read more

day: Conference Day Two